All In Biotech

Drug Trial Radar · NCT07783503

A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants

A Phase 1, Two-part, Open-label, Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 2, 2026

Primary completion

Nov 13, 2026

Study completion Nov 15, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effect of multiple doses of phenytoin, a strong cytochrome P450 (CYP)3A4 inducer, and itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetic (PK) profile of DAK539 (hereafter referred to as pelabresib) after a single dose in healthy participants. In addition, the safety and tolerability of a single dose of pelabresib with and without the co-administration of itraconazole or phenytoin will be evaluated.

Conditions

  • Healthy Participants

Interventions

  • PelabresibDrug

    Oral dosing

  • PhenytoinDrug

    Oral dosing

  • ItraconazoleDrug

    Oral dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 and 2: Maximum observed plasma concentration (Cmax) of pelabresibTime frame: From pre-dose up to 48 or 72 hours after pelabresib administration
  2. Part 1 and 2: Area under the plasma concentration-time curve from time 0 to the last measurable concentration sampling time (AUClast) of pelabresibTime frame: From pre-dose up to 48 or 72 hours after pelabresib administration
  3. Part 1 and 2: Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of pelabresibTime frame: From pre-dose up to 48 or 72 hours after pelabresib administration
  4. Part 1 and 2: Time to reach maximum plasma concentration (Tmax) of pelabresibTime frame: From pre-dose up to 48 or 72 hours after pelabresib administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Nottingham, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.